🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Emerson Electric Reports Q3 Sales Growth Of 7%, Raises FY22 EPS Guidance

Published 09/08/2022, 18:17
Updated 09/08/2022, 19:11
© Reuters.  Emerson Electric Reports Q3 Sales Growth Of 7%, Raises FY22 EPS Guidance
EMR
-

  • Emerson Electric Co (NYSE: NYSE:EMR) reported third-quarter FY22 net sales growth of 7% year-over-year to $5 billion, missing the consensus of $5.12 billion. Underlying sales were up 7%.
  • June trailing three-month underlying orders were up 10%.
  • Net sales by geography: Americas were up 14%, Europe was flat, and Asia, Middle East & Africa was down 1%. China was down 6%, primarily due to COVID-19 lockdowns.
  • Adjusted EPS improved 16% Y/Y to $1.38, beating the consensus of $1.30.
  • Related: Emerson Sells InSinkErator Business To Whirlpool For $3B
  • The pretax margin was 23.9%, up 720 bps. Adjusted EBITA margin was 22.8%, up by 270 bps.
  • Automation Solutions orders were up 13%, and the backlog increased by $100 million compared to the prior quarter to $6.2 billion. Net sales were flat in the quarter, with underlying sales up 4%. Adjusted segment EBITA margin increased 70 bps to 21%.
  • Commercial & Residential Solution's underlying orders were up 5% Y/Y, and the backlog decreased by $100 million to $1.3 billion. Net sales increased 8% Y/Y, with underlying sales up 13%. Adjusted segment EBITA margin fell 50 bps to 22%.
  • AspenTech net sales were $239 million, and the adjusted segment EBITA margin was 53.8%.
  • EMR's cash provided by operating activities year-to-date totaled $1.71 billion, compared to $2.72 billion a year ago. It held cash and equivalents of $2.53 billion as of June 30, 2022.
  • FY22 Outlook: Emerson Electric expects net sales growth of 7% - 8% (prior expectation 8% - 10%), with underlying sales growth of 9% - 10% (prior 9% - 11%).
  • It expects an adjusted EPS of $5.05 - $5.15 (prior $4.95 - $5.10) versus the consensus of $5.05. Operating Cash Flow of $3 billion (prior $3.6 billion) and FCF of $2.5 billion (prior $3 billion).
  • Price Action: EMR shares are trading lower by 3.39% at $86.98 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.